A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention
Latest Information Update: 05 May 2022
Price :
$35 *
At a glance
- Drugs Vorapaxar (Primary)
- Indications Cardiovascular disorders; Coronary artery disease
- Focus Adverse reactions
- Acronyms TRA-PCI
- Sponsors Merck Sharp & Dohme; Schering-Plough
- 14 Mar 2009 Results published in Lancet.
- 04 Apr 2007 Status changed from in progress to completed. Actual number of patients and final results reported.
- 23 Dec 2006 Status change